SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Therapeutic Advances in Cardiovascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1753944708093846v1
2/6/507    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Wachtell, K.
Right arrow Articles by Gerdts, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wachtell, K.
Right arrow Articles by Gerdts, E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy

Kristian Wachtell

Department of Cardiology B2142, The Heart Center, Rigshospitalet, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark, kristian{at}wachtell.net

Richard B. Devereux

Weill Cornell Medical College, New York, NY, USA

Paulette A. Lyle

Merck Research Laboratories, North Wales, PA, USA

Peter M. Okin

Weill Cornell Medical College, New York, NY, USA

Eva Gerdts

Institute of Medicine, University of Bergen and Department of Heart Disease, Haukeland University Hospital, Bergen, Norway

The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study provided extensive data on predisposing factors, consequences, and prevention of atrial fibrillation (AF) in patients with hypertension and left ventricular (LV) hypertrophy. Randomized losartan-based treatment was superior to atenolol-based treatment for reducing new-onset AF and complications, especially stroke, associated with new-onset or pre-existing AF. Potential mechanisms of AF prevention by angiotensin receptor blockade supported by LIFE results include greater reduction in left atrial size and LV hypertrophy. Differential effects of antihypertensive treatment on the left atrium and left ventricle may help prevent AF and reduce risk of stroke associated with hypertensive heart disease.

Key Words: atrial fibrillation • left atrial function • left atrial size • outcomes

This version was published on December 1, 2008

Therapeutic Advances in Cardiovascular Disease, Vol. 2, No. 6, 507-513 (2008)
DOI: 10.1177/1753944708093846
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement